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Abstract: The Coronavirus Disease (Covid-19) pandemic is rapidly spreading across the world, 
representing an unparalleled challenge for health care systems. There are differences in the 
estimated fatality rates, which cannot be explained easily. In Italy, the estimated case fatality rate 
was 12.7% in mid-April, while Germany remained at 1.8%. Moreover, it is to be noted that different 
areas of Italy have very different lethality rates. Due to the complexity of Covid-19 patient 
management, it is of paramount importance to develop a well-defined clinical workflow in order to 
avoid the inconsistent management of patients. The Integrated Care Pathway (ICP) represents a 
multidisciplinary outline of anticipated care to support patient management in the Sant’Andrea 
Hospital, Rome. The main objective of this pilot study was to develop a new ICP evaluated by care 
indicators, in order to improve the COVID-19 patient management. The suggested ICP was 
developed by a multi-professional team composed of different specialists and administrators 
already involved in clinical and management processes. After a review of current internal practices 
and published evidences, we identified (1) the activities performed during care delivery, (2) the 
responsibilities for these activities, (3) hospital structural adaptation needs and potential 
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improvements, and (4) ICP indicators. The process map formed the basis of the final ICP document; 
160 COVID-19 inpatients were considered, and the effect of the ICP implementation was evaluated 
over time during the exponential phase of the COVID-19 pandemic. In conclusion, a rapid adoption 
of ICP and regular audits of quality indicators for the management of COVID-19 patients might be 
important tools to improve the quality of care and outcomes. 
Keywords: coronavirus; COVID-19; clinical pathway; Italy; pandemic; SARS-Cov-2; risk 
management 
 
1. Introduction 
The Coronavirus Disease pandemic is rapidly spreading across the world, and it is an 
unparalleled challenge for the medical community and national health systems. Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is a very insidious pathology, and 
symptomatic manifestations can range from mild to critical. Some patients with initially mild 
symptoms may quickly progress over the course of five to ten days. In particular, earlier studies on 
a hospitalized Chinese population for pneumonia due to SARS-CoV-2 showed that dyspnea 
developed after a median of five days from the onset of symptoms, and hospital admission occurred 
after a median of seven days of symptoms [1,2]. Recovery time appears to be around two weeks for 
mild infections and three to six weeks for severe disease [3]. In Italy, 12%–16% of all hospitalized 
patients were admitted to the intensive care unit, and the estimated case fatality rate was 12.7% in 
mid-April [4–6]. This value is considerably different from that reported in South Korea (about 2%) 
even if the outbreak started concomitantly in the two countries [7]. This, in part, may be related to 
different impacts such as political management of the health crisis, availability of ventilators, and 
demographic factors (e.g., different median age of patients) [5]. It appears less comprehensible how 
different areas of Italy have very different lethality rates. In particular, the estimated case fatality rate 
in Lazio (Central Italy) is lower (5.7%) than in other central regions (e.g., Marche: 13.4%) and much 
lower than in Northern Italy (Lombardy: 18.4%) [7]. 
Even if a part of these differences can be explained by the pandemic “surprise effect” in Northern 
Italy, where the pandemic started, as well as to regional differences in socio-demographic conditions, 
it is noteworthy that the Italian National Health Service (INHS) is organized on a regional basis and 
that each Italian Region has large autonomy in health services management. This circumstance and 
its impact on the local intensity and severity of COVID-19 deserves in-depth analysis, also 
considering the significant difference in epidemic outcomes observed between Lombardy and 
Veneto, two neighboring regions with similar socio-economic profiles and with similar timing in the 
pandemic rise. The Governors of Lombardy and Veneto made different management choices for 
COVID-19 cases, and indeed, a re-arrangement of the INHS based on the regional pandemic 
experiences is becoming a debated political and social issue in Italy. 
Particularly, it is becoming increasingly apparent that different health management choices 
made early in the cycle of the pandemic had a relevant impact. Besides that, due to the magnitude 
and the complexity of COVID-19 management, it is of paramount importance to develop structured 
care in order to avoid additional irrational and inconsistent management of patients. To contribute 
to the improvement of present and future pandemic management, here we report the experience of 
the Sant’Andrea University Hospital of Rome (Region Lazio, Central Italy). In Lazio, the regional 
hospital network for COVID-19 management was early divided into hub-and-spoke structures, and 
Sant’Andrea University Hospital is one out of five hubs in Rome. To date, about 70% of all SARS-
CoV-2-positive patients in Lazio are treated in Rome [8]. We established a multi-disciplinary team to 
develop and implement an Integrated Care Pathway (ICP) for COVID-19 patients in order to improve 
the standard of care and minimize infection diffusion. We also report a preliminary assessment of the 
ICP impact by care indicators. 
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2. Materials and Methods  
A multi-professional team, composed of different types of physicians and administrators, who 
manage both clinical and organizational processes and are responsible for patient care, was created. 
The team includes: infectious disease specialists, hospital pharmacist, health director, oncologist, 
pneumologist, radiologist, laboratory medicine specialist, health administrators, internal medicine 
specialist, public health specialist, intensive care specialist. A facilitator to act as a link between all 
experts was also designated. Every decision was achieved with a majority of votes. The first steps of 
ICP development were a rapid review of both the current internal practice and the published 
evidences on COVID-19 management. During this process, selected literature was thoroughly 
screened for identification of all possible recommendations by the members of the working group; 
moreover, participants were given the opportunity to produce specific recommendations as expert 
opinions in the absence of evidence of effectiveness or indication in available guidelines. In particular, 
the specific COVID-19 documents produced by SIMIT (Italian Society for Infectious and Tropical 
Diseases), AIFA (Italian Medicines Agency), and EMA (European Medicines Agency) were taken into 
consideration. Evidence Definitions: Class I: Conditions for which there is evidence, general 
agreement, or both that a given procedure or treatment is useful and effective; Class II: Conditions 
for which there is conflicting evidence, a divergence of opinion, or both about the usefulness/efficacy 
of a procedure or treatment; Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy. 
Class IIb: Usefulness/efficacy is less well established by evidence/opinion. Class III: Conditions for 
which there is evidence, general agreement, or both that the procedure/treatment is not 
useful/effective and in some cases may be harmful. Level of Evidence A: Data derived from multiple 
randomized clinical trials. Level of Evidence B: Data derived from a single randomized trial or 
nonrandomized studies. Level of Evidence C: Consensus opinion of experts. Then, to define the 
process map for COVID-19, we also identified: (i) the activities performed during the delivery of care 
to the patients; (ii) the responsibilities for these activities; (iii) hospital structural adaptation needs; 
and (iv) potential problem areas or opportunities for improvements. The ICP was periodically 
improved according to the available updates. The impact of the developed ICP was assessed using 
the hospital fatality risk formula (fatal cases)/(fatal cases + recovered cases) as a care indicator, which 
provides a more accurate early estimate compared with (fatal cases)/(all cases). Statistical analysis 
was performed using the SPSS statistics software version 20 (IBM Corp, New York, NY, USA). With 
regard to ICP development, the study was performed in accordance with the World Medical 
Association Declaration of Helsinki and did not include any identifiable human data. For the 
following phase of patient enrolment, the protocol was approved by the Ethical committee of 
Sapienza University of Rome (reference number 5773_2020). 
3. Results 
3.1. Integrated Care Pathway  
The process map for the developed ICP is reported in detail in Table 1 and Figure 1. It refers to 
the clinical management of adult, non-pregnant SARS-CoV-2 positive patients (as detected by real-
time PCR analysis from naso-pharingeal swabs). All cases were notified to public health officials. To 
date, there are no solid data on drugs or other therapeutics to prevent or treat COVID-19. The clinical 
actions are based on clinical signs and severity of symptoms. Generally, management of most patients 
focuses on prevention of transmission to others and monitoring for clinical deterioration, to minimize 
and optimize hospitalization rate. Patients with mild illness who can be adequately isolated in the 
outpatient setting are directed to home management. For patients requiring hospitalization, the 
treatments mainly consist of supportive care, although for severe cases several investigational 
approaches are considered. In such cases, evaluation of drug–drug interactions of investigational 
COVID-19 therapies with co-medications is carried out to optimize patient’s specific therapy, 
avoiding predictable inefficacy/toxicity. For patients referred to the Emergency Department, 
interactions of investigational COVID-19 therapies with other drugs are evaluated using the 
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interaction charts from Liverpool University [9,10]. For patients in low-intensity, sub-intensive, and 
intensive care units, drug–drug interactions are evaluated also using the Drug-PIN software, a 
clinical decision support system aimed at the patient-specific design of poly-pharmacy [11]. Clinical 
trials enrollment, if available, is considered for all phases of the process map. The patient enters the 
process at the Emergency Department, as the first switching point in the ICP is the definition as 
“Suspected COVID-19 case” or “Confirmed COVID-19 case”. “Suspected COVID-19 case” is defined 
as follows: a patient with acute respiratory illness (fever and at least one sign/symptom of respiratory 
disease, e.g., cough, shortness of breath) AND a history of travel to or residence in a location reporting 
community transmission of COVID-19 disease during 14 days prior to symptom onset OR a patient 
with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-
19 case in the last 14 days prior to symptom onset OR a patient with severe acute respiratory illness 
(fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; and 
requiring hospitalization) and in the absence of an alternative diagnosis that fully explains the clinical 
presentation (according to WHO COVID-19 suspected case definition); suspected cases with 
inconclusive or negative results from RT-PCR for SARS-CoV-2 (discrepancy with clinical data) are 
tested on a further sample 24 h later. Confirmed COVID-19 case is defined as follows: a patient with 
laboratory confirmation of RT-PCR SARS-CoV-2 infection, irrespective of clinical signs and 
symptoms. Confirmed cases are differentially managed according to disease severity, as detailed in 
Table 1 and Figure 1a,b.  
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Figure 1. (a) Sant’Andrea Hospital Integrated Care Pathway (Hospital/Home). (b) Sant’Andrea 
Hospital Integrated Care Pathway (Hospital Care Units). 
Table 1. Integrated Care Pathway for patient management 
Action Area Indication 
(To Support Clinician Activities) 
b 
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Home 
Management  
(Asymptomatic 
Or Mild Infection) 
SARS-CoV-2 infection patient without symptoms or mild upper respiratory tract 
manifestations and/or fever (<37.5 °C) and/or minor clinical manifestation (malaise, 
muscle pain, nasal congestion, or headache); arterial blood gas (ABG): negative; high-
resolution computed tomography (chest-HRCT): low risk; walking test: negative; no 
risk factor for progression to severe disease (age ≥ 70 y, active malignancy, diabetes, 
cardiovascular and/or pulmonary disease). 
Team leader: emergency physician (Responsible); infectious disease specialist and 
pneumologist (Involved). 
• Management of most patients should focus on prevention of transmission to 
others and monitoring for clinical deterioration, which should minimize 
hospitalization.  
• Home management may be possible for patients with mild illness who can be 
adequately isolated  
• The patient requires strict measures of infection diffusion prevention and clinical 
and vital signs monitoring in order to early identify possible signs of clinical 
worsening (respiratory rate, SpO2, blood pressure, heart rate, body temperature) 
thrice/day.  
• The case is notified to public health and co-managed with the general practitioner 
Treatments: symptoms control (paracetamol, oral rehydration). 
SARS-CoV-2 infection patient without dyspnea and minor respiratory tract 
manifestations, moderate asthenia and/or persistent cough and/or fever ≥37.5 °C ≤ 38.5 
°C ***; no clinical or laboratory parameters of respiratory impairment. Arterial blood 
gas (ABG): negative; high-resolution computed tomography (chest-HRCT): low risk; 
walking test: negative; no risk factor for progression to severe disease (age ≥ 70 y, 
active malignancy, diabetes, cardiovascular and/or pulmonary disease); stable patient.  
Team leader: emergency physician (Responsible); infectious disease specialist and 
pneumologist (Involved). 
• Home management may be possible for patients with mild illness who can be 
adequately isolated.  
• The patient requires strict measures of infection diffusion prevention, clinical and 
vital signs monitoring in order to early identify possible signs of clinical worsening 
(respiratory rate, SpO2, blood pressure, heart rate, body temperature) thrice/day.  
• The case is notified to public health and co-managed with the general 
practitioner.  
Treatments: 
• Symptoms control (paracetamol, oral rehydration). 
• Therapy requires infectious disease specialist consultation: Hydroxychloroquine 
phosphate */** 400 mg tablets, 1 tablet q12 as loading dose, followed by 200 mg tablets, 
1 tablet q12, for 10 days, or Chloroquine phosphate */** 250 mg tablets, 2 tablet q12, for 
10 days; 
• In selected cases after risk–benefit assessment can be considered: 
• +/− Azitromicyn **/*** 500 mg 1 tablet day for 5 days (high suspected or 
confirmed bacterial infection and careful cardiological monitoring) 
or 
• +/− Antiviral therapy **: Lopinavir/ritonavir 200/50 mg tablets, 2 tablets q12h, for 
14 days or darunavir/cobicistat 800/150 mg tablets, 1 tablet, for 14 days; 
• +/− low molecular weight heparin, (LMWH): consider if serious increased risk of 
thrombosis (comorbidity). 
• Rapid worsening of respiratory functions requires hospitalization (unstable 
patient) and an increase of the care level. 
* ECG (QT interval) and glucose-6-phosphate dehydrogenase (G6PD) deficiency test 
should be considered 
** ECG should be performed 
*** In patient with fever perform at least 2 blood cultures and consider antimicrobial 
therapies. 
Hospitalized 
Patients  
Hospitalized patients with mild illness (no hypoxia) and risk factors for progression to 
severe disease OR hospitalized patients with hypoxia or radiographic evidence of 
pneumonia but not critically ill (clinically stable).  
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Low-Intensity 
Care Unit  
 
Team leader: infectious disease specialist (Responsible); internal medicine specialist 
and pneumologist (Involved). 
• Evidence of gas exchange worsening (mild to moderate dyspnea, high respiratory 
rate, shortness of breath, low peripheral SpO2 or altered arterial blood gases while 
breathing room air), without any critical or warning signs.  
• Clinical monitoring: close clinical monitoring and vital signs recording (blood 
pressure, heart rate, respiratory rate, SpO2, body temperature), in order to early 
identify a possible rapid worsening of respiratory functions, requiring an increase of 
the level of care; ABG analysis to be evaluated together with the intensive care 
specialist. 
Treatments:  
• O2 administration in order to maintain adequate peripheral oxygenation; 
• Hydroxychloroquine phosphate * 400 mg tablets, 1 tablet q12 as loading dose, 
followed by 200 mg tablets, 1 tablet q12, for 10 days, or Chloroquine phosphate ** 250 
mg tablets, 2 tablet q12, for 10 days; 
• In selected cases after risk–benefit assessment can be considered: 
• +/− Antiviral therapy **: Remdesivir (off label/trial), once daily intravenously: 200 
mg loading dose, followed by 100 mg daily maintenance dose, for 10 days, or (if 
Remdesivir not available) Lopinavir/ritonavir * 200/50 mg tablets, 2 tablets q12h, 
during 14 days or or Darunavir/Cobicistat 800/150 mg tablets, 1 tablet, for 14 days 
(requires infectious disease specialist consultation); 
• +/− low molecular weight heparin (LMWH): consider if D-dimer > 6-fold of upper 
limit of normal range or increased risk of deep-vein thrombosis (comorbidity); 
• +/− Antimicrobial therapy (preferentially based on microbiological culture results; 
requires infectious diseases specialist consultation); 
• Worsening of respiratory functions can require an increase of the care level 
(unstable patient). Rapid consultation with an intensive care specialist, IL-6 plasma 
levels; D-dimer, ferritin, fibrinogen, C-reactive protein, triglycerides, lactate 
dehydrogenase, and ABG are required. 
* ECG (QT interval) and G6PD deficiency test should be considered 
** ECG should be performed 
*** In patient with fever perform at least 2 blood cultures and consider antimicrobial 
therapies. 
Hospitalized 
Patients  
Sub-Intensive 
Care Unit 
Hospitalized patients with hypoxia or radiographic evidence of pneumonia but not 
critically ill (clinically stable) with need for high flow oxygen/Non Invasive Ventilation 
(NIV). 
Team leader: pneumologist (Responsible); infectious disease specialist (Involved). 
• Evidence of gas exchange worsening (moderate-to-severe dyspnea, high 
respiratory rate, shortness of breath, low peripheral SpO2, or altered arterial blood 
gases while breathing room air), without any critical or warning signs (severe 
respiratory failure, respiratory distress, consciousness disorders, hypotension, shock).  
• Clinical monitoring: close clinical monitoring, vital signs recording (blood 
pressure, heart rate, respiratory rate, SpO2, body temperature) and ABG analysis 
monitoring in order to early identify a possible rapid worsening of respiratory 
functions, requiring an increase of the care level; ABG analysis monitoring should be 
evaluated together with the intensive care specialist. 
Treatments:  
• O2 administration in order to maintain adequate peripheral oxygenation (non-
invasive ventilation); 
• Hydroxychloroquine phosphate * 400 mg tablets, 1 tablet q12 as loading dose, 
followed by 200 mg tablets, 1 tablet q12, for 10 days, or Chloroquine phosphate ** 250 
mg tablets, 2 tablet q12, for 10 days; 
• Antiviral therapy **: Remdesivir (off label/trial), once daily intravenously: 200 mg 
loading dose, followed by 100 mg daily maintenance dose, for 10 days or (if 
Remdesivir not available) Lopinavir/ritonavir * 200/50 mg tablets, 2 tablets q12h, 
during 14 days or Darunavir/Cobicistat 800/150 mg tablets, 1 tablet, for 14 days 
(requires infectious disease specialist consultation); 
Int. J. Environ. Res. Public Health 2020, 17, 3792 9 of 12 
Int. J. Environ. Res. Public Health 2020, 17, x; doi: www.mdpi.com/journal/ijerph 
• Worsening of respiratory functions can require an increase of the care level 
(unstable patient). Rapid consultation with an intensive care specialist, IL-6 plasma 
levels; D-dimer, ferritin, fibrinogen, C-reactive protein, triglycerides, lactate 
dehydrogenase, and ABG are required.  
In selected cases, after risk–benefit assessment together with the intensive care 
specialist, can be considered: 
• +/− Steroids: dexamethasone 20 mg daily intravenously for 5 days, followed by 10 
mg daily for 3 days and lastly 5 mg daily for 2 days; 
• +/− Tocilizumab 8 mg/kg, single dose intravenously; in absence or minimal 
clinical improvement a second dose should be administered after 8–12 h (maximum 3 
doses); 
• +/− low molecular weight heparin, (LMWH): consider if SIC score ≥4 or D-dimer > 
6-fold of upper limit of normal range or increased risk of deep-vein thrombosis 
(comorbidity); 
+/− Antimicrobial therapy (preferentially based on microbiological culture results; 
requires infectious diseases specialist consultation); 
* ECG and G6PD deficiency test should be considered 
** ECG should be performed 
*** In patient with fever perform at least 2 blood cultures and consider antimicrobial 
therapies. 
Hospitalized 
Patients  
Intensive Care 
Unit 
Hospitalized patients critically ill affected by a very severe illness, due to moderate 
respiratory failure (paO2/FiO2 < 200 mmHg) or severe respiratory failure (PaO2/FiO2 < 
100 mmHg) and/or severe impairment of other vital functions. 
Team leader: intensive care specialist (Responsible); infectious disease specialist 
(involved). 
Treatments: 
• Intensive vital signs monitoring;  
• O2 administration in order to maintain adequate peripheral oxygenation (NIV or 
early mechanical ventilation as recommended for patients affected by ARDS);  
• Hydroxychloroquine phosphate * 400 mg tablets, 1 tablet q12 as loading dose, 
followed by 200 mg tablets, 1 tablet q12, for 10 days, or Chloroquine phosphate ** 250 
mg tablets, 2 tablet q12, for 10 days (nasogastric tube), requires infectious diseases 
specialist consultation; 
• Antiviral therapy **: Remdesivir (off label/trial), once daily intravenously: 200 mg 
loading dose, followed by 100 mg daily maintenance dose, for 10 days or if Remdesivir 
not available, requires infectious diseases specialist consultation; 
• Antimicrobial therapy (preferentially based on microbiological culture results; 
requires infectious diseases specialist consultation);  
• In case of fever perform serial blood cultures; 
• Serial IL-6 plasma levels; D-dimer, ferritin, fibrinogen, C-reactive protein, 
triglycerides, lactate dehydrogenase, and ABG are required; 
In selected cases after risk–benefit assessment can be considered: 
• +/− Steroids: dexamethasone 20 mg daily intravenously for 5 days, followed by 10 
mg daily for 3 days and lastly 5 mg daily for 2 days 
• +/− Tocilizumab 8 mg/kg, single dose intravenously; in absence or minimal 
clinical improvement a second dose should be administered after 8–12 h (maximum 3 
doses) 
• +/− low molecular weight heparin, (LMWH) consider if SIC score ≥ 4 or D-dimer > 
6-fold of upper limit of normal range. 
* ECG and G6PD deficiency test should be considered 
** ECG should be performed 
 
• For all patients tested COVID positive, a psychological support was actively 
offered by psychologists trained for emergency management. The support was 
delivered 7 days/week from 8 am to 8 pm. 
• In all not critically ill hospitalized patients perform SARS-CoV-2–RT-PCR 
rhinopharyngeal swab every 3–5 days until persistently negative.  
• Therapy described within this document are based on very limited and 
preliminary clinical evidences which may be modified according to newly produced 
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literature data. Clinicians must consider guidelines for investigational treatments, 
literature (or regulatory) updates, case-by-case indications/contraindications, and if 
available, clinical trials enrolment for all phases of the pathway map. It helped 
organize our internal critical discussions around COVID-19 clinical management. 
 
SpO2: peripheral oxygen saturation; ECG: electrocardiogram; G6PD: glucose-6-
phosphate dehydrogenase; ABG: arterial blood gas; IL-6: Interleukine 6; SIC: sepsis-
induced coagulopathy score 
3.2. Preliminary Assessment of the Integrated Care Pathway 
Between 8th March and 7th April 2020, 627 COVID-19 suspect adult patients were evaluated in 
our center. Out of 315 SARS-Cov-2 RNA-positive patients, 160 required hospitalization. Of them, 22 
died during the period considered in the study. The median age of hospitalized died patients was 85 
years. Most of them were male, and all were older than 50 years. Comorbidities were present in 
almost all the cohort, with hypertension being the most common comorbidity. We assessed the 
impact of the ICP on COVID-19 inpatients mortality by hospital fatality risk (HFR) as the indicator. 
As target values for HFR are not broadly available at present, we calculated the HFR from the 
retrospective cohort study including adult inpatients (≥18 years old) with laboratory confirmed 
COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) during a well-
defined period of time (29th December 2019–31st January 2020). The HFR value in this reference 
cohort was 22% [12]. As shown in Table 2, along the period of ICP application, the Sant’Andrea 
University Hospital HFR was 12.1%, significantly lower compared with the reference HFR [1,13–15]. 
Table 2. Hospital fatality risk 
Indicator Hospital Fatality Risk (%) p-Value ** 
 Sant’Andrea Hospital  Reference indicator 
Wuhan Hospitals 0.0253 
(fatal cases)/(fatal cases + recovered cases) 22/182 (12.1%) 54/245 < 22% * 
* calculated from Fei Zhou et al. Lancet 2020; 395: 1054–62; ** chi-square statistic, p < 0.05. 
4. Discussion 
About three months after the COVID-19 pneumonia outbreak in Wuhan, Italy was affected by 
the SARS-Cov-2 pandemic. The epidemiologic differences we are noticing across the affected 
countries surely highlight different distribution of risk factors such as demographics, comorbidities, 
and many other features, making the comparison of data difficult. However, it becomes increasingly 
evident that different organization of health systems and different health policies, as well as the 
timeline of health management choices, have a great impact on the pandemic incidence. Comparative 
effectiveness research on different systems would provide precious information to develop better 
organizational models to face the pandemic. Thus, it is important to share methods and outcomes. 
The Italian paradigm may be an example, since in a generally similar social and demographic 
background, important differences in the pandemic management arose among different regions, 
leading to sensible differences in care outcomes. We developed an ICP which allowed to manage the 
suspected and confirmed COVID-19 cases referred to the emergency department, maintaining high 
quality standards and reducing the hospital fatality rate within acceptable limits. The availability of 
the ICP has been crucial to make early and shared decisions, to organize rationale triage areas with 
clear and definite protocols for triage, leading to testing suspect cases rapidly, and, depending on the 
diagnosis, to allocating them to the appropriate ward without delay. Thus, early and appropriate 
treatment of symptomatic patients has been possible together with strengthening of home 
management. 
In particular, the Sant’Andrea University Hospital HFR is significantly lower than the Wuhan 
hospitals compressive data (Table 2) and a large series of hospitalized patients in the New York City 
Area, while, HFR is similar to that reported in a recent update study from a single hyper-specialized 
COVID Hospital in Wuhan (Wuhan Pulmonary Hospital) [12–17]. This observation suggests that the 
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ICP here reported is suitable to allow a rapid and high-quality response also in relatively small health 
structures not specifically devoted to infective disease treatment. This is relevant to ensure an 
appropriate reaction of the INHS to the next phases of the pandemic, which could also present a 
further peak following removal of the lockdown. The ICP adoption during a well-defined interval of 
time in our emergency department resulted in a remarkable reduction of COVID-19-related mortality 
(before 60% vs. after 23.2%, data not shown). 
5. Conclusions 
Our findings suggest that a rapid adoption of ICP and regular audit of quality indicators for the 
management of COVID-19 patients might be important tools to improve the quality of care and 
outcomes. 
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